Graham Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Graham Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,112	Closed	-$239K	–	1164
2025 Q4	$239K	Buy	+11,112	New	+$216K	0.01%	961
2022 Q2	–	Sell	-82,171	Closed	-$561K	–	999
2022 Q1	$561K	Buy	+82,171	New	+$565K	0.02%	514
2020 Q3	–	Sell	-63,600	Closed	-$513K	–	89
2020 Q2	$513K	Buy	+63,600	New	+$561K	0.02%	75

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Graham Capital Management's AVDL Position: Q1 2026 in Review

Graham Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 11,112 shares — an estimated $239K sold.

Graham Capital Management first reported a position in AVDL in Q2 2020 and held it in 3 quarters. The position peaked at $561K in Q1 2022. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Graham Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 11,112 Avadel Pharmaceuticals shares in Q1 2026, an estimated $239K.
Graham Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 3 quarters.
Graham Capital Management's Avadel Pharmaceuticals position peaked at $561K in Q1 2022.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.